N-acetylcysteine (NAC): Antioxidant replenishment and antifibrotic potential

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/n-acetylcysteine-nac-antioxidant-replenishment-and-antifibrotic-potential

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Introduction N-acetylcysteine (NAC) is a supplement of the amino acid cysteine that has long been used as a mucolytic (to thin mucus) and as an antidote for acetaminophen overdose. More recently, doctors and researchers have studied NAC for its role in boosting antioxidants and controlling scarring. NAC enters cells and is converted to cysteine, which is the building block for glutathione, a major natural antioxidant in the body () (). By helping the body make more glutathione, NAC can help neutralize harmful free radicals. In the eye, this antioxidant action may protect delicate tissues. NAC has been shown to reduce oxidative damage in animal models of glaucoma () and to improve retinal cell function in patients with inherited retinal disease (). At the same time, NAC appears to interfere with fibrosis (the scarring process driven by TGF-β) in laboratory studies, suggesting it might soften the wound-healing response that can cause bleb failure after glaucoma surgery () (). This article reviews what we know about NAC’s antioxidant and antifibrotic effects, how it may affect the eye and body, its usual dosing and side effects, and whether it is safe to start after glaucoma surgery. We also suggest how future studies could test NAC’s impact on bleb healing and survival. NAC and Glutathione Synthesis Glutathione (GSH) is a small molecule that cells use to quench free radicals and repair oxidative damage. Our bodies must continually make glutathione, and that requires the amino acid cysteine. NAC is a modified form of cysteine that can enter cells easily. Once inside, NAC is converted to cysteine and boosts glutathione production () (). For example, a review article notes that “NAC’s antioxidant effect is due to [its] ability to act as a reduced glutathione (GSH) precursor” (). In other words, NAC provides the raw material for more glutathione, which in turn helps neutralize harmful oxidants. (Indeed, this is the same principle behind giving NAC for acetaminophen poisoning — it spares glutathione so the liver toxin can be cleared.) In practical terms, taking NAC supplements can raise cellular cysteine and glutathione levels. One study in a mouse model of normal-pressure glaucoma found that NAC increased glutathione in retinal cells and suppressed oxidative stress (). Antioxidant Effects of NAC Because glutathione is so central to our cell’s defense against damage, boosting it can have wide-ranging effects. NAC itself can also act as a direct antioxidant. One mechanism is that NAC (or glutathione made from it) can scavenge harmful molecules like hydrogen peroxide or reactive aldehydes. Another is that NAC helps break unwanted chemical bonds (disulfides) in damaged proteins or mucus, which can restore normal function (). A short review explains that together these actions give NAC broad chemoprotective power: it neutralizes toxic electrophiles, restores glutathione, and even breaks down problematic protein cross-links (). In more biological terms, NAC relaxes mucus in the lungs, protects the liver, and reduces oxidative stress in many tissues. In the eye, oxidative stress is a key factor in many diseases including glaucoma and retinal degeneration. Recent laboratory studies found that NAC can dial down eye-specific oxidation. In a rat glaucoma model with high eye pressure, daily NAC injections plus a glaucoma drop (brimonidine) reduced retinal oxidative damage compared to controls (). In genetic models of glaucoma where pressure is normal, NAC preserved retinal ganglion cells by blocking stress signals (via HIF-1α and autophagy pathways) (). In patients, a small clinical trial gave oral NAC to men with retinitis pigmentosa and found improvements in cone cell function (likely due to reduced oxidative stress) (). These findings suggest NAC can act as an eye-protective antioxidant both systemically and locally. NAC and the TGF-β Fibrotic Pathway After any surgery, including glaucoma (filtering) surgery, the body’s natural healing response involves fibroblast cells laying down scar tissue. In filtering surgery, excessive fibrosis can close the new drain (bleb) and cause the surgery to fail. A key driver of fibrosis is transforming growth factor beta (TGF-β), a signaling protein that tells cells to become scar-forming myofibroblasts. Studies in eye cells show that NAC can blunt this pathway. For example, one laboratory study treated human retinal pigment epithelial cells with TGF-β1, which normally causes them to turn into migratory myofibroblasts (involved in scarring). Adding NAC to these cells kept them from changing. In fact, NAC inhibited TGF-β1-driven transdifferentiation: it prevented the rise in smooth muscle actin, fibronectin, and collagen that TGF-β1 normally causes (). The research suggested that NAC’s antioxidant action lowered reactive oxygen species and blocked MAP kinase signaling triggered by TGF-β1, thus stopping the fibrotic switch (). (In plain terms, NAC prevented cells from becoming scar-making myofibroblasts.) Similarly, other studies have found that NAC can suppress TGF-β–induced fibrosis in lung and other tissues. One 2009 study in human lung fibroblasts showed NAC reverses TGF-β1–driven fibrosis markers: it stopped gel contraction, and blocked production of fibronectin and α-smooth muscle actin (). By extension, NAC might also blunt TGF-β–driven scarring in the eye. Though direct clinical data in glaucoma surgery are lacking, the lab evidence supports the idea that NAC can modulate the TGF-β fibrotic pathway, potentially reducing scar formation. Moreover, NAC influences enzymes involved in tissue remodeling. For instance, corneal cell studies indicate that NAC reduces MMP-9 (matrix metalloproteinase-9) secretion and slows cell migration (). MMP-9 breaks down extracellular matrix and is linked to inflammation; dampening MMP-9 may help stabilize healing tissues. In summary, NAC seems to exert an antifibrotic influence by both damping the TGF-β signals and lowering enzymes that drive scar remodeling () (). Ocular and Systemic Evidence on NAC Ocular Data Beyond its antifibrotic and antioxidant effects seen in cell studies, NAC has been tested in several eye-related conditions. In dry eye, NAC eye drops have been used (anecdotally and in small trials) to improve tear quality by breaking up mucus, thanks to its disulfide-reducing action (). For glaucoma, most of the evidence is preclinical: animal and lab models suggest NAC could protect retinal cells and limit scarring. As noted above, glaucoma models showed less retinal stress and ganglion-cell loss with NAC treatment (). A landmark phase I trial in retinitis pigmentosa showed that high-dose oral NAC improved cone photoreceptor function in patients (), demonstrating that NAC can reach and help eye cells in humans. These studies indicate NAC can reach ocular tissues (for example, measurable NAC levels were found in eye fluid) and exert its effects. Systemic Data and Dosing Systemically, NAC is sold as a dietary supplement and used as a prescription drug. Typical oral dosing is 600–1200 mg per day, often divided into two or three doses. In clinical trials, doses up to 1800 mg three times daily have been tested (), but the usual recommended range for antioxidant purposes is 600–1200 mg daily. NAC is well absorbed orally, though its bioavailability is modest. Because it supplies cysteine, high-dose NAC supplementation can raise glutathione levels gradually over days to weeks. NAC is generally well tolerated. Common side effects are gastrointestinal. According to drug references, NAC can cause nausea, vomiting, diarrhea or constipation in some people (). Occasionally it causes headache, dizziness or rash, but serious allergic reactions to oral NAC are rare. In the JCI retinitis pigmentosa trial, adverse effects were mostly mild GI upset; some patients needed dose reduction, but none had severe issues (). In summary, at doses around 600–1200 mg/day, NAC’s side effects are usually mild and transient (). NAC After Glaucoma Surgery (Trabeculectomy) Trabeculectomy is a surgery to lower eye pressure by creating a drainage bleb. The big risk after surgery is scarring that closes the bleb. Ophthalmologists already use anti-scarring agents like mitomycin C at surgery to improve success rates. NAC’s profile suggests it could be useful as a safer anti-scarring agent if given after surgery. Starting NAC two weeks after surgery seems reasonable because initial wound closure is complete by then, but scar remodeling is still active. By two weeks, the conjunctival wound has closed, and systemic NAC might gently restrain the fibroblasts before they lay down thick scar tissue. There are no clinical trials yet on NAC for post-trabeculectomy care, but the available evidence (antioxidant and antifibrotic) suggests a potential benefit with low risk. Safety considerations: NAC does not usually impair normal wound healing or carry serious surgical risks. However, caution is advised with certain cardiovascular drugs. In particular, NAC can interact with nitroglycerin (and related nitrate medications). NAC can potentiate the blood pressure lowering effect of nitrates – in

Transcript

SPEAKER_00 0:00

Introduction N-acetylcysteine is a supplement of the amino acid cysteine that has long been used as a mucolytic to thin mucus and as an antidote for acetaminofin overdose. More recently, doctors and researchers have studied NAC for its role in boosting antioxidants and controlling scarring. NAC enters cells and is converted to cysteine, which is the building block for glutathione, a major natural antioxidant in the body. By helping the body make more glutathione, NAC can help neutralize harmful free radicals. In the eye, this antioxidant action may protect delicate tissues. NAC has been shown to reduce oxidative damage in animal models of glaucoma and to improve retinal cell function in patients with inherited retinal disease. At the same time, NAC appears to interfere with fibrosis, the scarring process driven by TGFB in laboratory studies, suggesting it might soften the wound healing response that can cause bleb failure after glaucoma surgery. This article reviews what we know about NAC's antioxidant and antifibrotic effects, how it may affect the eye and body, its usual dosing and side effects, and whether it is safe to start after glaucoma surgery. We also suggest how future studies could test NAC's impact on bleb healing and survival. NSE and glutathione synthesis glutathione, GSH, is a small molecule that cells use to quench free radicals and repair oxidative damage. Our bodies must continually make glutathione, and that requires the amino acid cysteine. NAC is a modified form of cysteine that can enter cells easily. Once inside, NAHE is converted to cysteine and boosts glutathione production. For example, a review article notes that NAC's antioxidant effect is due to its ability to act as a reduced glutathione GSH precursor. In other words, NIC provides the raw material for more glutathione, which in turn helps neutralize harmful oxidants. Indeed, this is the same principle behind giving NAC for acetaminofin poisoning. It spares glutathione so the liver toxin can be cleared. In practical terms, taking NIC supplements can raise cellular cysteine and glutathione levels. One study in a mouse model of normal pressure glaucoma found that NAC increased glutathione in retinal cells and suppressed oxidative stress. Antioxidant effects of NAC. Because glutathione is so central to our cells' defense against damage, boosting it can have wide-ranging effects. NAC itself can also act as a direct antioxidant. One mechanism is that NAC or glutathione made from it can scavenge harmful molecules like hydrogen peroxide or reactive aldehydes. Another is that NAC helps break unwanted chemical bonds, disulfides, in damaged proteins or mucus, which can restore normal function. A short review explains that together these actions give NAC broad chemoprotective power. It neutralizes toxic electrophiles, restores glutathione, and even breaks down problematic protein crosslinks. In more biological terms, NAC relaxes mucus in the lungs, protects the liver, and reduces oxidative stress in many tissues. In the eye, oxidative stress is a key factor in many diseases, including glaucoma and retinal degeneration. Recent laboratory studies found that NAC can dial down eye-specific oxidation. In a rat glaucoma model with high eye pressure, daily NAC injections plus a glaucoma drop bromonidine reduced retinal oxidative damage compared to controls. In genetic models of glaucoma where pressure is normal, NAC preserved retinal ganglion cells by blocking stress signals via HEF-1 HA and autophagy pathways. In patients, a small clinical trial gave oral NAC to men with retinitis pigmentosa and found improvements in cone cell function, likely due to reduced oxidative stress. These findings suggest can act as an eye-protective antioxidant both systemically and locally. NAC and the TGFF fibrotic pathway. After any surgery, including glaucoma filtering surgery, the body's natural healing response involves fibroblast cells laying down scar tissue. In filtering surgery, excessive fibrosis can close the new drain, bleb, and cause the surgery to fail. A key driver of fibrosis is transforming growth factor beta, TGF beta, a signaling protein that tells cells to become scar-forming myofibroblasts. Studies in eye cells show that NAC can blunt this pathway. For example, one laboratory study treated human retinal pigment epithelial cells with TGFB1, which normally causes them to turn into migratory myofibroblasts involved in scarring. Adding NAC C to these cells kept them from changing. In fact, NAC inhibited TGF-bit1-driven transdifferentiation. It prevented the rise in smooth muscle actin, fibronectin, and collagen that TGF-bit1 normally causes. The research suggested that NAC C's antioxidant action lowered reactive oxygen species and blocked MAP kinase signaling triggered by TGF-bate1, thus stopping the fibrotic switch. In plain terms, NAC prevented cells from becoming scar-making myofibroblasts. Similarly, other studies have found that NAC can suppress TGF-beta-induced fibrosis in lung and other tissues. One 2009 study in human lung fibroblasts showed NAC reverses TGF-bate1-driven fibrosis markers, it stopped gel contraction and blocked production of fibronectin and alpha-smooth muscle actin. By extension, NAC might also blunt TGF-Baya-driven scarring in the eye. Though direct clinical data in glaucoma surgery are lacking, the lab evidence supports the idea that NAC can modulate the TGF-baia fibrotic pathway, potentially reducing scar formation. Moreover, NAC influences enzymes involved in tissue remodeling. For instance, corneal cell studies indicate that NAC reduces MMP9, matrix metalloprotonase 9 secretion, and slows cell migration. MMP9 breaks down extracellular matrix and is linked to inflammation. Dampening MMP9 may help stabilize healing tissues. In summary, NAS seems to exert antantifibrotic influence by both damping the TGF-base signals and lowering enzymes that drive scar remodeling. Ocular and systemic evidence on NAC ocular data. Beyond its antifibrotic and antioxidant effects seen in cell studies, NAC has been tested in several eye-related conditions. In dry eye, NAC eye drops have been used anecdotally and in small trials to improve tear quality by breaking up mucus thanks to its disulfide reducing action. For glaucoma, most of the evidence is preclinical. Animal and lab models suggest NA could protect retinal cells and limit scarring. As noted above, glaucoma models showed less retinal stress and ganglion cell loss with NASI treatment. A landmark phase one trial in retinitis pigmentosa showed that high-dose oral NAC improved cone photoreceptor function in patients, demonstrating that NAC can reach and help eye cells in humans. These studies indicate NAC can reach ocular tissues, for example, measurable NAC levels were found in eye fluid and exert its effects. Systemic data and dosing. Systemically, NACI is sold as a dietary supplement and used as a prescription drug. Typical oral dosing is 600 to 1200 mg per day, often divided into two or three doses. In clinical trials, doses up to 1800 mg three times daily have been tested, but the usual recommended range for antioxidant purposes is 600-1200 mg daily. NAC is well absorbed orally, though its bioavailability is modest. Because it supplies cysteine, high-dose NAC supplementation can raise glutathione levels gradually over days to weeks. NAC is generally well tolerated. Common side effects are gastrointestinal. According to drug references, NAC can cause nausea, vomiting, diarrhea, or constipation in some people. Occasionally it causes headache, dizziness, or rash, but serious allergic reactions to oral NAC are rare. In the JCI retinitis pigmentosa trial, adverse effects were mostly mild GI upset. Some patients needed dose reduction, but none had severe issues. In summary, at doses around 600 to 1200 mg per day, NAC's side effects are usually mild and transient. NAC after glaucoma surgery, trabeculectomy. Trabeculectomy is a surgery to lower eye pressure by creating a drainage bleb. The big risk after surgery is scarring that closes the bleb. Ophthalmologists already use anti-scarring agents like mitomycin C at surgery to improve success rates. NAC's profile suggests it could be useful as a safer anti-scarring agent if given after surgery. Starting NAC two weeks after surgery seems reasonable because initial wound closure is complete by then, but scar remodeling is still active. By two weeks, the conjunctival wound has closed and systemic NAC might gently restrain the fibroblasts before they lay down thick scar tissue. There are no clinical trials yet on NAC for post-trabeculectomy care, but the available evidence, antioxidant and antifibrotic, suggests a potential benefit with low risk. Safety considerations. NAC does not usually impair normal wound healing or carry serious surgical risks. However, caution is advised with certain cardiovascular drugs. In particular, NENAC can interact with nitroglycerin and related nitrate medications. NAC can potentiate the blood pressure lowering effect of nitrates. In fact, it is sometimes given with nitroglycerin for chest pain because it enhances nitrate action. What this means in practice is that a patient taking a nitrate blood pressure pill or patch should use caution, as NAC could cause added hypotension. Similarly, NAC has mild vasodilating effects of its own, so it might add to the effect of antihypertensive medications. Doctors generally recommend avoiding a strong combination of NAC with nitrates or multiple blood pressure drugs without monitoring. Two weeks after surgery is beyond the period of bleeding risk, so NAC should not increase bleeding. NAC's mucolytic effect could theoretically thin secretions, but this is not known to affect eye surgery outcomes. Overall, NENAC at usual oral doses is likely safe to begin two weeks post-trabeculectomy, provided blood pressure and heart rate are monitored, especially if the patient is on nitrates or several antihypertensives. As always, any new supplement after surgery should be discussed with the surgeon first. Designing studies on NAC and bleb outcomes. To test whether NAC truly improves bleb survival and shape, clinical and laboratory studies could be designed. Randomized clinical trial, patients. Enroll patients undergoing trabeculectomy and randomly assign them to receive either oral NAC, for example, 600 mg twice daily, or a placebo starting two weeks after surgery. Mask patients and investigators to treatment. Follow them for three to six months, measuring bleb morphology, height, vascularity, by slit lamp photography or anterior segment OCT, bleb function, intraocular pressure control, and need for additional glaucoma therapy. Primary outcomes could be bleb survival, time until IOP rises, and bleb appearance scores. Safety endpoints would include monitoring blood pressure and any side effects. Animal, e.g., rabbit, model. Perform trabeculectomy on rabbits and divide them into NAC versus control groups. Give NAC orally or via subconjunctival injection at the surgical site for a set period, e.g., two to four weeks. Periodically measure bleb leakage or pressure, then euthanize for histology. Compare bleb tissue between groups for collagen deposition, fibroblast numbers, and vascularity. This would provide controlled data on how NAC affects scar formation and bleb architecture. Cell and tissue studies culture human tenin's capsule fibroblasts and treat them with TGF-Ba-1 with or without NAC C. Measure markers of fibrosis, SMA, collagen to test NAC's effect on scarring signals. In parallel, organ culture of extracted human conjunctiva or animal scleral tissues exposed to NAC could assess matrix remodeling. Such studies would clarify whether NAC can meaningfully alter bleb healing. If successful, these steps could pave the way to larger human trials. Conclusion: NACE is an established drug with a strong safety record. It replenishes cellular glutathione and acts as an antioxidant, protecting cells from oxidative stress. In the eye and elsewhere, NAC has shown promise in lab studies for antifibrotic effects. It can block TGF-1-induced myofibroblast changes and reduce enzymes like MMP9 that drive scarring. These properties suggest that could help maintain filtering blebs by preventing excessive fibrosis. Oral NAC at doses around 600 to 1200 milligrams daily is generally well tolerated. Most side effects are mild GI upset and might be safe to initiate a couple of weeks after trabeculectomy. Clinicians should watch for interactions with nitrates or other blood pressure medications, as NAC can enhance vasodilation. Rigorous studies, from cell labs to patient trials, are needed to test NAC's real-world benefits on bleb health. If proven effective, NAC would offer a simple and low-risk way to improve surgical outcomes by harnessing the body's own antioxidant and antifibrotic defenses. Tags incorporate keywords like Nacetylcysteine, antioxidant therapy, glutathione, fibrosis, TGF beta, glaucoma, trabeculectomy, ocular wound healing, oxidative stress. Tags, Nacetylcysteine, Glaucoma surgery, antioxidants, TGF beta, wound healing, ocular fibrosis, glutebeculectomy. All links to sources are available in the text version of this article. You can find the full article at visualfieldtest.com. Thanks for listening. To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.